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Abstract
Progressive muscular atrophy (PMA) and amyotrophic lateral sclerosis (ALS) are devastating motor neuron diseases (MNDs),
which result in muscle weakness and/or spasticity. We compared mutation frequencies in genes known to be associated
with MNDs between patients with apparently sporadic PMA and ALS. A total of 261 patients with adult-onset sporadic PMA,
patients with sporadic ALS, and control subjects of Dutch descent were obtained at national referral centers for
neuromuscular diseases in The Netherlands. Sanger sequencing was used to screen these subjects for mutations in the
coding regions of superoxide dismutase-1 (SOD1), angiogenin (ANG), fused in sarcoma/translated in liposarcoma (FUS/TLS),
TAR DNA-binding protein 43 (TARDBP), and multivesicular body protein 2B (CHMP2B). In our cohort of PMA patients we
identified two SOD1 mutations (p.D90A, p.I113T), one ANG mutation (p.K17I), one FUS/TLS mutation (p.R521H), one TARDBP
mutation (p.N352S), and one novel CHMP2B mutation (p.R69Q). The mutation frequency of these genes was similar in
sporadic PMA (2.7%) and ALS (2.0%) patients, and therefore, our findings demonstrate a genetic overlap between
apparently sporadic PMA and ALS.
Citation: van Blitterswijk M, Vlam L, van Es MA, van der Pol W-L, Hennekam EAM, et al. (2012) Genetic Overlap between Apparently Sporadic Motor Neuron
Diseases. PLoS ONE 7(11): e48983. doi:10.1371/journal.pone.0048983
Editor: Udai Pandey, Lousiana State University Health Sciences Center, United States of America
Received September 5, 2012; Accepted October 3, 2012; Published November 14, 2012
Copyright:  2012 van Blitterswijk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research leading to these results has received funding from the European Community’s Health Seventh Framework Program (FP7/2007–2013)
(grant agreement no. 259867), the VSB fonds, The Brain Foundation of the Netherlands, Prinses Beatrix Fonds, Catharijne Stichting, H. Kersten and M. Kersten, J. R.
van Dijk, and the Adessium Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: L.H.vandenBerg@umcutrecht.nl
. These authors contributed equally to this work.
Introduction
Motor neuron diseases (MNDs) are a heterogeneous group of
disorders characterized by muscle weakness and/or spasticity due
to degeneration of motor neurons. Progressive muscular atrophy
(PMA) refers to a subgroup of the MND patients with rapidly or
gradually developing muscle weakness. PMA accounts for 5–10%
of adult-onset MNDs, and is caused by a progressive loss of lower
motor neurons (LMNs) [1,2]. Differentiation of PMA from
amyotrophic lateral sclerosis (ALS) is important, since the median
survival of patients with PMA is significantly longer than that of
patients with ALS [3].
The etiology of MNDs is complex. Most of the ALS cases, for
instance, are sporadic in nature and thought to be caused by an
interaction of genetic and environmental factors [4]. Currently,
many genes appear to be involved in the pathogenesis of ALS,
including chromosome 9 open reading frame 72 (C9orf72),
superoxide dismutase-1 (SOD1), angiogenin (ANG), fused in
sarcoma/translated in liposarcoma (FUS/TLS), TAR DNA-
binding protein 43 (TARDBP/TDP-43), vesicle-associated mem-
brane protein B (VAPB), optineurin (OPTN), valosin-containing
protein (VCP), ubiquilin-2 (UBQLN2), sequestosome-1 (SQSTM1),
and profilin-1 (PFN1) [5,6,7,8,9,10,11]. We have recently shown
that C9orf72 repeat expansions can also be detected in apparently
sporadic PMA, but at a lower frequency (1.6%) than in apparently
sporadic ALS (6.1%) [12]. Moreover, we have demonstrated that
mutations in four major MND-associated genes, SOD1, ANG,
FUS/TLS and TARDBP, account for less than two percent of the
sporadic ALS cases [13]. The combined mutation frequency of
these four MND-associated genes is unknown for sporadic PMA
patients. Mutations in charged multivesicular body protein 2B
(CHMP2B) have, however, been reported in sporadic PMA
patients [14,15].
The objective of this study is to determine the mutation
frequency of major MND-associated genes in patients with
apparently sporadic PMA. We compared their mutation frequen-
cies to those in a large cohort of patients with apparently sporadic
ALS, revealing a genetic overlap.
Materials and Methods
Patient Selection
We included 261 patients with apparently sporadic PMA and
screened their DNA for mutations in SOD1, ANG, FUS/TLS,
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TARDBP, and CHMP2B. PMA patients had already been screened
for mutations in transient receptor potential vanilloid 4 (TRPV4)
and repeat expansions in C9orf72 [12,16]. Their diagnosis was
based on LMN involvement on clinical and electrophysiological
examination at time of referral. We excluded patients with a family
history of PMA, a history of acute poliomyelitis, spinal radiculo-
pathy, diabetic amyotrophy, thyrotoxicosis, or hyperparathyroid-
ism, clinical signs of upper motor neuron (UMN) involvement,
sensory signs on neurological examination, structural lesions on
magnetic resonance imaging or computed tomography of head
and spine, and motor conduction block on extensive standardized
nerve conduction studies [2].
Cohorts of sporadic ALS patients had already been screened for
mutations in SOD1 (N= 451), ANG (N= 941), FUS/TLS
(N= 1,192), TARDBP (N= 1,192), and C9orf72 (N= 1,422)
[12,13,17,18,19]. We screened 1,002 sporadic ALS patients for
mutations in CHMP2B. ALS patients were recruited through the
Dutch Prospective Population-based ALS registry; they were
diagnosed according to the El Escorial Criteria at national referral
centers for neuromuscular diseases (University Medical Center
Utrecht, Academic Medical Center Amsterdam, or Radboud
University Nijmegen Medical Center) [20,21].
Mutations in SOD1 (N= 1,894), ANG (N= 1,582), FUS/TLS
(N= 970), and TARDBP (N= 1,415) had previously been reported
in Dutch control subjects [13,18,19]. We screened a total of 750
control subjects of Dutch descent for mutations in CHMP2B.
Ethics Statement
All material was obtained with approval of the medical ethics
committee for research in humans of the University Medical
Center Utrecht, The Netherlands, and all participants gave
written informed consent.
Genetic Analysis
Coding regions of SOD1 (NM_000454.4), ANG (NM_001145.4),
FUS/TLS (NM_004960.3, exon 5, 6, 14, 15), TARDBP
(NM_007375.3, exon 6), and CHMP2B (NM_014043.3) were
screened for mutations using touchdown PCR, as described
previously [13,22]. Sanger sequencing and data analysis were
performed with BigDye Terminator 3.1 sequencing kit (Applied
Biosystems, Foster City, California), DNA Analyzer 3730XL
(Applied Biosystems) and PolyPhred [23]. Each mutation was
confirmed on genomic DNA and its impact on the structure, and
function of the protein was predicted with PolyPhen-2 (PolyPhen-2
version 2.1.0; http://genetics.bwh.harvard.edu/pph2/) and PMut
(http://mmb.pcb.ub.es/PMut/PMut.jsp).
Genealogical Analysis
Lists of descendants were compiled for index patients. Based on
these lists, civil records/registers, and church records of the Dutch
population, pedigrees were generated (containing two parents,
four grandparents, eight great-grandparents, etc.). This informa-
tion was then used to determine whether index patients were
related, and detailed family trees were constructed.
Haplotype Analysis
Extended haplotype analysis, using six extragenic polymorphic
markers flanking TARDBP (D1S1612, D1S503, D1S244 proximal
of TARDBP, and D1S2667, D1S2740 and D1S1597 distal of
TARDBP), was performed to construct a haplotype segregating
with the identified p.N352S mutation in TARDBP. Validity of the
constructed haplotype was determined by segregation analysis in
families and patients whose DNA was available for testing.
Statistical Analysis
A Fisher’s exact test or Chi-square test was used to compare
mutation frequencies, gender, site of onset, and current status
(alive/deceased) between PMA and ALS patients; a Mann-
Whitney test was used to compare age at onset and disease
duration (GraphPad Prism version 5; http://www.graphpad.com).
P-values below 0.05 were considered significant.
Results
Study Population
Baseline characteristics of the 261 sporadic PMA patients and
1,002 sporadic ALS patients are shown in Table 1. Patients with
PMA were more likely to be male (72% versus 59%); furthermore,
they lived longer (7.6 year versus 3.8 year), and had a lower age at
onset (58.0 year versus 60.6 year) than patients with ALS.
Mutation Frequencies
Table 2 summarizes the mutations found in patients and control
subjects. In individual PMA patients we detected heterozygous
mutations in SOD1 (p.D90A [c.1078A.C], p.I113T
[c.1147T.C]), ANG (p.K17I [c.122A.T]), FUS/TLS (p.R521H
[c.1562G.A]) and TARDBP (p.N352S [c.1055A.G]), accounting
for 2.3% of the patients. Previously, we showed that missense
mutations in SOD1, ANG, FUS/TLS and TARDBP were present in
1.7% of the ALS patients, and 0.4% of the control subjects
[13,17,18,19]. In our current study, we also identified four novel
CHMP2B mutations, one of which was present in a PMA patient
(p.R69Q [c.206G.A]), and three in ALS patients (p.R22Q
[c.65G.A], p.N54T [c.161A.C], p.T83I [c.248C.T]). All four
CHMP2B mutations are located in a domain that is important for
the formation of multivesicular bodies (MVBs), involved in sorting
of cargo proteins to intraluminal vesicles [24]. These mutations are
located in well conserved areas (Figure S1) and predicted to be
pathological (Table 2). They account for 0.38% of the sporadic
PMA patients and 0.30% of the sporadic ALS patients. None of
these CHMP2B mutations was present in our control subjects;
however, in one control subject (0.13%) we did detect a mutation
(p.S194L [c.581C.T]) that had previously been reported in
a patient with frontotemporal dementia (FTD) [25].
Clinical Characteristics
The average age at onset of PMA patients with missense
mutations was 48 years, and five of them were male (71%).
Although only one of these patients had died, their average disease
duration already exceeded 114 months (range 37–316). These
clinical characteristics of sporadic PMA patients with missense
mutations were consistent with the characteristics of our entire
PMA cohort. More detailed signs and symptoms are provided in
Table 3.
Genealogical- and Haplotype Analyses
Previously, we have shown that the p.N352S mutation in
TARDBP is a founder mutation in the Dutch ALS population [13].
Hence, we performed a thorough genealogical analysis and
demonstrated that our PMA patients with p.N352S mutations
had common ancestors, dating back to the 17th century in the
north of France (Figure S2). Haplotype analysis revealed that these
patients also shared the haplotype that was reported in Dutch ALS
patients [13].
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Discussion
Patients with isolated LMN signs represent a subgroup of the
patients with MND. To assess the mutation frequency of MND-
associated genes in this subgroup, we compared 261 apparently
sporadic PMA patients to apparently sporadic ALS patients. Our
PMA patients were more likely to be male and lived significantly
longer than ALS patients, as reported previously [3]. We detected
two SOD1 mutations (p.D90A, p.I113T), one ANG mutation
(p.K17I), one FUS/TLS mutation (p.R521H), one TARDBP
mutation (p.N352S), and one novel CHMP2B mutation
(p.R69Q) in individual PMA patients. For each of these genes
we compared mutation frequencies between our PMA patients
and ALS patients, and did not detect significant differences.
Clinical and pathological similarities between PMA and ALS
have already been reported: more than twenty percent of the
patients with isolated LMN signs will develop UMN signs within
six years, especially in the first years after symptom onset [1,3,26].
Nonetheless, it can be difficult to diagnose these UMN signs due to
LMN wasting and pathophysiological abnormalities caused by
Table 1. Baseline characteristics of study population.
Cohort Number (N) Male/female (N) (%) Age at onset (y) (CI) Alive/deceased (N) (%) Duration (y) (CI)
PMA 261 187/74 (72/28) 58.0 (56.4–59.7) 137/116 (54/46) 7.6 (6.7–8.5)
ALS 1,002 593/409 (59/41) 60.6 (59.8–61.3) 135/854 (14/86) 3.8 (3.6–4.1)
Abbreviations: PMA=progressive muscular atrophy, ALS = amyotrophic lateral sclerosis, N = number, y = years, and CI = 95% confidence interval. Disease duration is
defined as the interval between age at onset and age at death, or between age at onset and age last known to be alive. Patients with sporadic PMA are more likely to be
male (p-value 0.001), to have a lower age at onset (p-value 0.010), to be alive (p-value,0.001), and to have a longer disease duration than patients with sporadic ALS (p-
value ,0.001).
doi:10.1371/journal.pone.0048983.t001
Table 2. Missense mutations found in SOD1, ANG, FUS/TLS, TARDBP, and CHMP2B.
Gene Variant Exon PMA ALS CON Prediction PolyPhen-2 Prediction PMut
SOD1 p.D90A 4 1/261a 1/451 [17] 3/1,894 [13] Benign Pathological
p.I113T 4 1/261 0/451 0/1,894 Probably damaging Pathological
p.I99V 4 0/261 1/451 0/1,894 Benign Neutral
Total (%) 2/261 (0.77) 2/451 (0.44) 3/1,894 (0.16)
ANG p.G(210)D 2 0/261a 1/941 [18] 0/1,582 [18] N/A N/A
p.K17I 2 1/261 3/941 2/1,582 Benign Pathological
p.T80S 2 0/261 1/941 0/1,582 Possibly damaging Neutral
p.F100I 2 0/261 1/941 0/1,582 Probably damaging Neutral
Total (%) 1/261 (0.38) 6/941 (0.64) 2/1,582 (0.13)
FUS/TLS p.S115N 5 0/261a 1/1,192 [13] 0/970 [19] Unknown Neutral
p.Q210H 6 0/261 0/1,192 1/970 Unknown Neutral
p.R487C 14 0/261 1/1,192 0/970 Probably damaging Pathological
p.R495X 14 0/261 1/1,192 0/970 N/A N/A
p.R521H 15 1/261 0/1,192 0/970 Probably damaging Pathological
Total (%) 1/261 (0.38) 3/1,192 (0.17) 1/970 (0.10)
TARDBP p.N352S 6 2/261a 3/1,192 [13] 0/1,415 [13] Benign Pathological
p.I383V 6 0/261 1/1,192 0/1,415 Benign Neutral
Total (%) 2/261 (0.77) 4/1,192 (0.34) 0/1,415 (0.00)
CHMP2B p.R22Q 2 0/261a 1/1,002a 0/750a Possibly damaging Pathological
p.N54T 3 0/261 1/1,002 0/750 Probably damaging Neutral
p.R69Q 3 1/261 0/1,002 0/750 Probably damaging Pathological
p.T83I 3 0/261 1/1,002 0/750 Probably damaging Pathological
p.S194L 6 0/261 0/1,002 1/750 Benign Neutral
Total (%) 1/261 (0.38) 3/1,002 (0.30) 1/750 (0.13)
Total (%) 7 (2.7) 18 (2.0) 7 (0.5)
Abbreviations: CON= control subjects, and N/A =not applicable. Mutations in SOD1, ANG, FUS/TLS, TARDBP, and CHMP2B were present in 2.7% of the PMA patients, 2.0%
of the ALS patients, and 0.5% of the control subjects. No PMA patients were detected with mutations in multiple MND-associated genes. A Fisher’s exact test or Chi-
square test was used to compare mutation frequencies between patients with PMA and ALS for each gene; no significant differences were detected (data not shown for
simplicity).
aCohort described in the present study.
doi:10.1371/journal.pone.0048983.t002
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damaged motor pathways, motor neurons and interneurons [27].
Pathological studies have also revealed ubiquitinated inclusions
and involvement of the corticospinal tract in PMA patients, which
are typical for ALS patients and emphasize similarities between
these diseases [28,29].
Previously, mutations in SOD1, ANG, FUS/TLS, TARDBP and
CHMP2B have been identified in patients with a range of clinical
phenotypes, including combinations of FTD, Parkinson’s disease,
and ALS
[14,18,22,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45].
CHMP2B mutations have also been described in sporadic PMA
patients, while mutations in MND-associated genes have been
detected in familial ALS patients with predominantly LMN signs
[15,19,28,46,47,48,49,50]. In addition, we have recently shown
that C9orf72 repeat expansions are present in sporadic PMA
patients, but at a lower frequency than in sporadic ALS patients
(1.6% versus 6.1%) [12]; other studies have shown that C9orf72
repeat expansions were present in approximately 7% of white
sporadic ALS patients from the USA, Europe and Australia, and
that bulbar onset ALS is frequently encountered in patients with
these expansions [51,52,53,54]. Our current findings demonstrate
that mutations in SOD1, ANG, FUS/TLS, TARDBP and CHMP2B
are also associated with apparently sporadic PMA, thus expanding
the wide range of clinical phenotypes reported to date. Further-
more, the comparable mutation frequencies between PMA and
ALS patients show that, apart from clinical and pathological
similarities, these diseases demonstrate a genetic overlap as well,
suggesting that PMA is a subtype of ALS.
We detected a SOD1 mutation (p.D90A) in a patient with
sporadic PMA, a patient with classical sporadic ALS, and control
subjects. This is the most common SOD1 mutation, and causes
both autosomal dominant and recessive ALS [55,56]. Although it
behaves dominantly in many families, it is a polymorphism in the
Swedish population, primarily causing ALS when in the homo-
zygous state [57]. Another SOD1 mutation (p.I113T) was also
present in a PMA patient; it is known for its clinical heterogeneity,
including asymptomatic subjects, patients with mild fasciculations,
patients with typical ALS, and patients with ALS-FTD and chorea
[41,58]. Both these SOD1 mutations appear to result in ALS
through aggregation of mutant SOD1 protein [59].
In addition, we identified an ANG mutation (p.K17I) in one
PMA patient, and in two out of 1,582 Dutch control subjects. The
p.K17I mutation has already been reported in ALS patients and in
control subjects [18]. Despite its presence in control subjects, it
does affect the neuroprotective-, angiogenic- and ribonucleolytic
activity of ANG [50,60,61]. It seems likely that this mutation raises
ALS susceptibility and/or acts as a genetic modifier, a hypothesis
supported by recent reports of families that harbor a p.K17I
mutation in combination with TARDBP- or FUS/TLS mutations,
and a large international collaborative study, which demonstrates
that ANG mutations confer a substantial risk for ALS [13,18,62].
In one PMA patient, we identified a FUS/TLS mutation
(p.R521H); one of the most common FUS/TLS mutations with
a disease duration of approximately four years [63,64]. In two
other PMA patients we detected a TARDBP mutation (p.N352S),
which has been described in German and Japanese ALS patients
[65,66,67]. We have recently reported that p.N352S is a founder
mutation in the Dutch ALS population [13]. In the present study,
we revealed that our PMA patients had common ancestors and
shared a haplotype also detected in Dutch ALS patients.
The four CHMP2B mutations we detected (p.R69Q, p.R22Q,
p.N54T, p.T83I) are novel, absent in control subjects, located in
well conserved areas, and predicted to be pathogenic. One of these
was identified in a patient with sporadic PMA (0.38%), three in
patients with sporadic ALS (0.30%). These mutation frequencies
demonstrate that CHMP2B mutations are not specific for PMA,
but are present in patients with PMA, FTD, ALS-FTD, and ALS.
We also detected one previously reported mutation (p.S194L) in
a control subject [25]. Since this variant is located within an area
of low complexity and predicted to have neutral effects, it probably
represents a rare benign polymorphism.
Recently, we have provided evidence for an oligogenic etiology
of familial ALS [13]. We reported five families with mutations in
multiple MND-associated genes: ANG mutations were detected in
combination with FUS/TLS and TARDBP mutations, and C9orf72
repeat expansions in combination with TARDBP, SOD1, and FUS/
TLS mutations (p-value 1.5761027). In our present study, we did
not identify mutations in multiple MND-associated genes in
a single patient; however, the high phenotypic variability that is
seen amongst patients with mutations in these genes (ranging from
FTD to Parkinson’s disease and MNDs) does suggest that other
genetic and/or environmental factors influence disease character-
istics of sporadic MNDs.
Table 3. Clinical characteristics of newly identified patients with missense mutations.
Group Gene Variant Gender LMNa signs UMNa signs Age at onset (y) Site of onset Duration (m)
PMA SOD1 p.D90A M 1 0 17 Cervical 316
p.I113T F 2 0 48 Lumbosacral 108
ANG p.K17I M 1 0 66 Lumbosacral 52
FUS/TLS p.R521H M 3 0 47 Cervical 68
TARDBP p.N352S F 2 0 68 Cervical 37
p.N352S M 4 0 61 Lumbosacral 101b
CHMP2B p.R69Q M 1 0 26 Cervical 116
ALS CHMP2B p.R22Q M 3 2 57 Cervical 68
p.N54T F 3 2 68 Bulbar 28b
p.T83I M 2 1 71 Cervical 75
Abbreviations: M =male, F = female, LMN= lower motor neuron, UMN=upper motor neuron, and m=months. Clinical characteristics of ALS patients with SOD1, ANG,
FUS/TLS and TARDBP mutations have been described elsewhere [13,17,18,19].
aNumber of affected body regions at time of diagnosis (maximum four: bulbar, cervical, thoracic or lumbosacral).
bDeceased.
doi:10.1371/journal.pone.0048983.t003
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To summarize, we have detected comparable mutation
frequencies in patients with apparently sporadic PMA and ALS,
indicating a genetic overlap between these two diseases. Thus, our
findings favor the hypothesis that PMA is a subtype of ALS and
not a distinct entity, broadening the disease spectrum of ALS.
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Figure S1 CHMP2B mutations and conservation. Con-
servation of amino-acid residues across species was generated
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clustalw2/.
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Figure S2 Pedigree of two PMA patients with p.N352S
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